InvestorsHub Logo
Followers 46
Posts 1362
Boards Moderated 0
Alias Born 08/09/2015

Re: None

Sunday, 11/05/2017 9:43:27 AM

Sunday, November 05, 2017 9:43:27 AM

Post# of 459471
Note this about the focus of CTAD 2017:

''The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. .....

CTAD 2017 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.''

Paul Aisen (Anavex expert board) was one of the major figures at the CATD 2017 conference.

I like the overall aim ''... to overcome the hurdles and speed the development of effective treatments.'' Everyone, including the FDA is onboard with doing just that.

I am cautiously optimistic.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News